fludarabine has been researched along with Dysmyelopoietic Syndromes in 167 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (7.78) | 18.2507 |
| 2000's | 67 (40.12) | 29.6817 |
| 2010's | 71 (42.51) | 24.3611 |
| 2020's | 16 (9.58) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, J; Atsuta, Y; Fukuda, T; Imada, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y | 1 |
| Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Atsuta, Y; Fukuda, T; Imada, K; Ishiyama, K; Itonaga, H; Kako, S; Kanda, J; Kanda, Y; Kawakita, T; Kimura, T; Kobayashi, T; Kurosawa, S; Maruyama, Y; Matsuoka, KI; Najima, Y; Nakazawa, H; Ota, S; Ozawa, Y; Shimomura, Y | 1 |
| Davini, M; de la Maza, M; Hanmod, S; Katsanis, E; Pariury, H; Proytcheva, M; Sapp, LN; Staples, K; Truscott, L | 1 |
| Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F | 1 |
| Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 2 |
| Behre, G; Döhring, C; Franke, GN; Grimm, J; Hille, A; Jentzsch, M; Linke, R; Niederwieser, D; Pönisch, W; Schwind, S; Vucinic, V | 1 |
| Bolwell, B; Gerds, AT; Hamilton, BK; Hanna, R; Kalaycio, M; Majhail, NS; Patel, SS; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Andersen, NS; Friis, LS; Grønbæk, K; Hansen, JW; Kornblit, B; Petersen, SL; Schjødt, I; Sengeløv, H; Wedge, E | 1 |
| Akashi, K; Eto, T; Fujishima, N; Harada, M; Hidaka, M; Kishimoto, J; Maeda, Y; Matsumoto, K; Miyamoto, T; Mori, SI; Morita, K; Murayama, T; Sakura, T; Taniguchi, S; Teshima, T; Uchida, N; Yamashita, T; Yoshimoto, G | 1 |
| Callander, N; D'Angelo, CR; Hall, A; Hematti, P; Juckett, M; Kenkre, VP; Kim, K; Longo, W; Mattison, R; Woo, KM | 1 |
| Chu, X; Fang, X; Geng, L; Liu, H; Qiang, P; Song, K; Sun, G; Sun, Z; Tang, B; Tong, J; Wan, X; Yao, W; Zhang, X; Zhu, X | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Agrawal, V; Ahn, KW; Aljurf, M; Bacher, U; Bashey, A; Beitinjaneh, A; Bredeson, C; Cerny, J; Chhabra, S; Copelan, E; Diaz, MA; Farhadfar, N; Farhan, S; Fretham, C; Gale, RP; Ganguly, S; Grunwald, MR; Hale, GA; Hashmi, S; Hildebrandt, GC; Jain, T; Kalaycio, M; Kharfan-Dabaja, MA; Lazarus, HM; Liesveld, JL; Litzow, M; Majhail, NS; Marks, DI; Murthy, HS; Nakamura, R; Nathan, S; Nishihori, T; Olsson, RF; Oran, B; Pawarode, A; Popat, U; Reshef, R; Rizzieri, D; Saber, W; Sabloff, M; Savani, BN; Scott, BL; Seo, S; Szer, J; van der Poel, M; Verdonck, LF; Weisdorf, D; Wirk, B; Yared, JA; Yves-Cahn, J | 1 |
| Alyea, EP; Bashey, A; Deeg, HJ; Devine, SM; Fernandez, HF; Geller, NL; Giralt, S; Hamadani, M; Horowitz, MM; Horwitz, ME; Le-Rademacher, J; Leifer, E; Logan, BR; Maziarz, RT; Mendizabal, AM; Pasquini, MC; Porter, DL; Scott, BL; Warlick, ED; Wu, J | 1 |
| Afanasyev, B; Bethge, W; Brand, R; de Witte, T; Deliliers, GL; Dreger, P; Franke, GN; Guidi, S; Günther, A; Heim, D; Hübel, K; Iacobelli, S; Kobbe, G; Kröger, N; Onida, F; Pini, M; Platzbecker, U; Poiré, X; Robin, M; Scheid, C; Stelljes, M; Uddin, R; van Os, M; Volin, L; Weber, T | 1 |
| Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Apel, A; Bernardi, M; Bonini, C; Ciceri, F; Danylesko, I; Greco, R; Lo Russo, A; Lupo Stanghellini, MT; Nagler, A; Peccatori, J; Shem-Tov, N; Shimoni, A; Vago, L; Yerushalmi, R | 1 |
| Barker, JN; Boulad, F; Castro-Malaspina, H; Fuller, K; Hilden, PD; Hsu, KC; Jakubowski, AA; Kernan, NA; Koehne, G; O'Reilly, RJ; Papadopoulos, EB; Perales, MA; Prockop, SE; Scaradavou, A; Spitzer, B; van den Brink, MR; Young, JW | 1 |
| Aoki, J; Atsuta, Y; Eto, T; Fukuda, T; Ichinohe, T; Ishiyama, K; Iwato, K; Kahata, K; Kako, S; Kanamori, H; Kanda, Y; Kawamura, K; Kondo, T; Mizuta, S; Ozawa, Y; Sawa, M; Uchida, N; Yano, S | 1 |
| Alyea, EP; Antin, JH; Armand, P; Cutler, CS; Glotzbecker, BE; Gooptu, M; Ho, VT; Kim, HT; Koreth, J; Nageshwar, P; Nikiforow, S; Ritz, J; Soiffer, RJ | 1 |
| Deotare, U; Khalil, MMI; Kim, DD; Lipton, JH; Messner, HA; Michelis, FV; Thyagu, S; Viswabandya, A | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Alatrash, G; Andersson, BS; Champlin, RE; Chen, J; Crain, AK; Di Stasi, A; Jones, RB; Kidwell, KM; Popat, U; Shpall, EJ; Thall, PF; Zope, M | 1 |
| Imanaga, H; Ohno, Y; Ohta, T; Oku, S; Sugio, Y | 1 |
| Alyea, EP; Antin, JH; Armand, P; Attar, EC; Ballen, KK; Chen, YB; Coughlin, E; Cutler, C; Dey, BR; Ho, VT; Kennedy, KF; Koreth, J; McAfee, SL; Soiffer, RJ; Spitzer, TR | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Compain, L | 1 |
| Kalaycio, M; Lukenbill, J | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L | 1 |
| Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH | 1 |
| Divoka, M; Faber, E; Indrak, K; Langova, K; Pikalova, Z; Raida, L; Rohon, P; Rusinakova, Z; Skoumalova, I; Szotkowska, R | 1 |
| Benjamini, O; Burger, J; Estrov, Z; Ferrajoli, A; Jain, P; Kantarjian, H; Keating, M; Lerner, S; O'Brien, S; Qiao, W; Strom, SS; Trinh, L; Wang, X; Wierda, W | 1 |
| Hirabayashi, K; Koike, K; Kurata, T; Nakazawa, Y; Saito, S; Sakashita, K; Tanaka, M; Yanagisawa, R; Yoshikawa, K | 1 |
| Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G | 1 |
| Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J | 1 |
| Blaise, D; Ceballos, P; Chevallier, P; Cornelissen, J; Einsele, H; Gluckman, E; Holler, E; Kenzey, C; Linkesch, W; Maillard, N; Pagliuca, A; Pascal, L; Petersen, E; Rocha, V; Ruggeri, A; Sengeloev, H; Tabrizi, R; Tucunduva, L; Yakoub-Agha, I | 1 |
| Alatrash, G; Andersson, BS; Champlin, R; Charafeddine, Y; Chen, J; Ciurea, S; Kebriaei, P; Lee, HC; Medeiros, LJ; Oran, B; Popat, U; Rondon, G; Saliba, RM; Shpall, E | 1 |
| Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE | 1 |
| Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R | 1 |
| Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Harbi, S; Lemarie, C; Vey, N; Wanquet, A; Weiller, PJ | 1 |
| Bermúdez, A; Caballero, MD; Cabrero, M; Conde, E; De La Serna, J; Gómez, V; Lahuerta, JJ; Moraleda, JM; Perez, SG; Sanz, G; Sanz, J; Serrano, D; Vallejo, C | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Kim, DY; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M | 1 |
| Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC | 1 |
| Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL | 1 |
| Bay, JO; Beckerich, F; Blaise, D; Bourhis, JH; Bulabois, CE; Chevallier, P; Contentin, N; Daguindau, E; de La Tour, RP; Delage, J; Detrait, M; François, S; Guillaume, T; Guillerm, G; Huynh, A; Labopin, M; Legrand, F; Lioure, B; Maillard, N; Mohty, M; Turlure, P; Vigouroux, S; Yakoub-Agha, I | 1 |
| Abounader, DM; Andresen, S; Bolwell, BJ; Dean, R; Ferraro, C; Gerds, AT; Hamilton, BK; Hanna, R; Hill, BT; Kalaycio, M; Liu, H; Majhail, NS; Mustafa Ali, M; Pohlman, B; Rybicki, LA; Sobecks, RM; Starn, J; Winslow, V; Yurch, MA | 1 |
| Baker, KS; Boulad, F; Davies, SM; Guinan, E; Kernan, NA; Lane, A; Leemhuis, T; Lehmann, L; Margolis, D; Mehta, PA; Myers, K; O'Reilly, RJ; Prockop, SE; Scaradavou, A; Williams, DA | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Baron, F; Baudoux, E; Beguin, Y; Bonnet, C; Fillet, G; Frère, P; Gothot, A; Hafraoui, K; Herens, C; Seidel, L; Vanbellinghen, JF; Vanstraelen, G; Wanten, N; Willems, E | 1 |
| Branagan, AR; Emmanouilides, C; Frankel, SR; Gregory, SA; Ioakimidis, L; Kimby, E; Lister, A; Matous, J; Morel, P; Patterson, CJ; Soumerai, JD; Treon, SP; Turnbull, B; Wasi, P | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Champlin, RE; de Lima, M; de Padua Silva, L; de Souza, JA; Efebera, Y; Hosing, C; Patah, P; Popat, U; Qazilbash, MH; Ribeiro, R; Rondon, G; Saliba, RM | 1 |
| Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL | 1 |
| Appelbaum, FR; Deeg, HJ; Fisher, DR; Gooley, TA; Gopal, AK; Martin, PJ; Matthews, DC; Pagel, JM; Press, OW; Rajendran, J; Sandmaier, BM; Storb, RF; Wilson, WA | 1 |
| Abonour, R; Baute, JA; Cornetta, K; Cox, EA; Cripe, LD; Dlouhy, SR; Farag, SS; Fausel, CA; Haut, PR; Hromas, R; Nelson, RP; Robertson, KA; Robertson, MJ; Schwartz, JE; Srivastava, S; Vance, GH; Wood, LL; Yu, M | 1 |
| Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE | 1 |
| Angchaisuksiri, P; Apilugsanachit, A; Atichartakarn, V; Boonsakan, P; Chuncharunee, S; Jootar, S; Kanoksil, W; Karntisaviwat, K; Niparuck, P; Nitiyanant, P; Rerkamnuatchoke, B; Ungkanont, A | 1 |
| Carney, DA; Seymour, JF | 1 |
| Came, N; Carney, DA; Januszewicz, EH; Kenealy, M; Milner, A; Prince, HM; Ritchie, D; Seymour, JF; Tam, CS; Westerman, DA; Wolf, M | 1 |
| Aurora, M; Bachanova, V; Blazar, BR; Brunstein, C; Burns, L; Cao, Q; Cooley, S; Defor, T; Dusenbery, K; Kaufman, D; Macmillan, M; Majhail, NS; McClune, B; McGlave, P; Miller, J; Oran, B; Slungaard, A; Tomblyn, M; Vercellotti, G; Verneris, M; Wagner, J; Warlick, ED; Weisdorf, DJ | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Palmieri, S; Riccardi, C | 1 |
| de Lima, M; de Souza Santos, FP; Hamerschlak, N; Kerbauy, FR; Kutner, JM; Ribeiro, AA; Rodrigues, M; Sobrinho, JN; Torres, MA | 1 |
| Alatrash, G; Andersson, BS; Champlin, RE; Chiattone, A; de Lima, M; de Padua Silva, L; Giralt, SA; Hamerschlak, N; Hosing, C; Kebriaei, P; Kerbauy, F; Nieto, Y; Pelosini, M; Qazilbash, MH; Rondon, G; Saliba, RM; Wang, X; Xiao, L; Zhang, W | 1 |
| Allen, JC; Chowbay, B; Diong, CP; Goh, YT; Hwang, WY; Linn, YC; Loh, SM; Wong, AM | 1 |
| Bae, SH; Choi, SJ; Hyun, MS; Jeon, M; Joo, YD; Kang, MJ; Kang, YA; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Lee, YS; Park, JH; Ryoo, HM; Seol, M; Yun, SC | 1 |
| Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J | 1 |
| Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR | 1 |
| Hwang, HJ; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, YS; Seol, M; Shin, HJ; Yun, SC | 1 |
| Colović, M; Colović, N; Fekete, MD; Janković, G; Palibrk, V; Suvajdžić, N; Tomin, D | 1 |
| Sinsabaugh, C | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Neumann, T; Wilfert, H | 1 |
| Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; Devillier, R; El Cheikh, J; Esterni, B; Etienne, A; Faucher, C; Fürst, S; Prebet, T; Vey, N | 1 |
| Danylesko, I; Nagler, A; Shem-Tov, N; Shimoni, A; Volchek, Y; Yerushalmi, R | 1 |
| Aisa, Y; Kato, J; Mori, T; Nakamura, Y; Nakazato, T; Okamoto, S; Shigematsu, N | 1 |
| Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Lee, JH; Lee, KH; Lee, WS; Park, JH; Ryoo, HM | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Fathi, AT; Hasserjian, R; Sadrzadeh, H | 1 |
| Alvarnas, J; Bhatia, R; Cai, JL; Chang, K; Chao, J; Forman, SJ; Maegawa, R; Nakamura, R; O'Donnell, MR; Palmer, JM; Parker, PM; Pullarkat, V; Senitzer, D; Snyder, DS; Stein, AS; Stiller, T; Thomas, SH; Wang, S | 1 |
| Helton, KJ; Patay, Z; Triplett, BM | 1 |
| Bae, SH; Hyun, MS; Joo, YD; Kim, DY; Kim, H; Kim, MK; Kim, SD; Lee, GW; Lee, JH; Lee, KH; Lee, WS; Min, YJ; Park, JH; Ryoo, HM | 1 |
| Ichikawa, M; Kurokawa, M; Nakagawa, M; Nakamura, F; Nannya, Y; Yamazaki, S | 1 |
| Bargay, J; Brunet, S; Caballero, MD; Canals, C; Léon, A; Martino, R; Moraleda, JM; Pérez-Simón, JA; San Miguel, J; Sanz, GF; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A | 1 |
| Chao, NJ; Clay, TM; Hobeika, AC; Lyerly, HK; Morse, MA; Mosca, PJ; Rizzieri, D; Stenzel, TT; Vredenburgh, JJ | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Anasetti, C; Appelbaum, FR; Bornhauser, M; Deeg, HJ; Ehninger, G; Hansen, J; Jenke, A; Martin, PJ; McDonald, GB; Nichols, WG; Radich, J; Schleyer, E; Slattery, JT; Storer, B; Thiede, C; Woolfrey, A | 1 |
| Beyer, J; Biersack, H; Bornhäuser, M; Ehninger, G; Kiehl, M; Kröger, N; Sayer, HG; Schäfer-Eckardt, K; Schwerdtfeger, R; Wandt, H; Zander, AR | 1 |
| Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
| Devereux, S; Ho, AY; Kenyon, M; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE | 1 |
| Biesma, DH; Daenen, SM; Delforge, M; Graveland, WJ; Löwenberg, B; Muus, P; Noordhuis, P; Ossenkoppele, GJ; Peters, GJ; Schaafsma, MR; Selleslag, D; Sonneveld, P; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH | 1 |
| Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, R; Korbling, M; Madden, T; Pierre, B; Russell, JA; Shahjahan, M; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Aschan, J; Blau, I; Casper, J; Doelken, G; Freund, M; Giebel, S; Holowiecki, J; Knauf, W; Kroger, N; Ruutu, T; Schafer-Eckart, K; Volin, L; Wandt, H; Zander, A | 1 |
| Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E | 1 |
| Barnardo, M; Campbell, AJ; Collins, GP; Eagleton, H; Jones, J; Keen-Mcguire, A; Littlewood, TJ; Malladi, RK; Miller, E; Morgenstern, G; Norton, AE; Peniket, AJ; Samol, J | 1 |
| Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F | 1 |
| Behringer, D; Bertz, H; Finke, J; Küttler, T; Samek, E; Spyridonidis, A; Wäsch, R; Waterhouse, M | 1 |
| Califano, C; D'Arco, AM; Danise, P; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B | 1 |
| Artz, A; Bennett, D; Cao, D; Casey, B; Daugherty, C; Del Cerro, P; Godley, L; Jones, D; Larson, RA; Odenike, O; Rich, S; Smith, S; Stock, W; Thirman, M; van Besien, K; Wickrema, A; Zimmerman, T | 1 |
| Auerbach, AD; Defor, TE; Macmillan, ML; Slungaard, A; Tan, PL; Wagner, JE | 1 |
| Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T | 1 |
| Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Tischer, J | 1 |
| Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ | 1 |
| Chun, K; Daly, A; Gupta, V; Hasegawa, W; Kamel-Reid, S; Kiss, T; Lipton, JH; Messner, H; Minden, M; Tsang, R; Yi, QL | 1 |
| Begum, G; Chopra, R; Cook, G; Cook, M; Craddock, C; Goldstone, A; Hale, G; Hunter, A; Jackson, G; Khwaja, A; Littlewood, T; Mackinnon, S; Mahendra, P; Marsh, J; Milligan, D; Parker, A; Peggs, K; Peniket, A; Russell, N; Tauro, S | 1 |
| Atanackovic, D; Ayuk, F; Dahlke, J; Kröger, N; Nagler, A; Panse, J; Renges, H; Schieder, H; Shimoni, A; Wolschke, C; Zabelina, T; Zander, A | 1 |
| Rzepecki, P; Sarosiek, T; Szczylik, C | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J | 1 |
| Cai, Z; Wu, WJ | 1 |
| Au, WY; Chan, LC; Kwong, YL; Liang, R | 1 |
| Mitra, S; Murphy, PT; O'Donghaile, D | 1 |
| Bowcock, SJ; Lim, Z; Mufti, GJ; Rassam, SM; Ryali, MM; Ward, SM | 1 |
| Czepulkowski, B; Devereux, S; Duarte, RF; Ho, AY; Ingram, W; Kenyon, M; Lim, ZY; Mufti, GJ; Pagliuca, A; Pearce, L | 1 |
| Alyea, EP; Antin, JH; Cutler, C; DeAngelo, DJ; Ho, V; Kim, HT; Ritz, J; Soiffer, RJ; Stone, R | 1 |
| Januszewicz, EH; Kenealy, M; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; de Meis, E; Donato, M; Ghosh, S; Giralt, S; Hosing, C; Kebriaei, P; Khouri, I; Oran, B; Popat, U; Qazilbash, M; Saliba, R | 1 |
| Appelbaum, FR; Bedalov, A; Bryant, EM; Chang, C; Clurman, BE; Deeg, HJ; Flowers, ME; Hansen, JA; Nash, RA; Sanders, JE; Sandmaier, BM; Scott, BL; Shulman, HM; Storb, R; Storer, BE; Witherspoon, RP | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T | 1 |
| Giles, FJ; Gojo, I; Greer, J; Johnson, B; Karp, JE; Low, J; Morris, L; Sznol, M; Thein, M | 1 |
| Bhatia, R; Chang, K; Forman, SJ; Kirschbaum, M; Kogut, N; Naing, A; Nakamura, R; O'Donnell, MR; Palmer, J; Pullarkat, V; Rodriguez, R; Slovak, ML; Spielberger, R; Stein, A; Tsai, N | 1 |
| Artz, AS; Daugherty, C; Godley, L; Huo, D; Larson, R; Odenike, OM; Pollyea, DA; Rich, E; Smith, SM; Stock, W; van Besien, K; Zhang, Y; Zimmerman, T | 1 |
| Anderlini, P; Andersson, BS; Caldera, Z; Champlin, RE; Chan, KW; Cook, JD; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Jabbour, E; Kebriaei, P; Khouri, I; Martin, TG; McCormick, G; Patah, PA; Qazilbash, M; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Hardan, I; Nagler, A; Rand, A; Shem-Tov, N; Shimoni, A; Yerushalmi, R | 1 |
| Bernal, MT; Besalduch, J; Brunet, MS; Caballero, D; Carrera, D; Ferra, C; Martin, J; Martino, R; Moraleda, JM; Nieto, JB; Perez-Simón, JA; Piñana, JL; Ribera, JM; Sampol, A; Sierra, J; Valcárcel, D; Vazquez, L | 1 |
| Huisman, C; Lokhorst, HM; Meijer, E; Petersen, EJ; Verdonck, LF | 1 |
| Agura, ED; Bethge, WA; Blume, KG; Bruno, B; Chauncey, TR; Curtin, PT; Epner, E; Forman, SJ; Lange, T; Laport, GG; Maloney, DG; Maris, MB; Petersen, FB; Sandmaier, BM; Scott, BL; Storb, RF; Storer, BE; Stuart, MJ; Wade, JC; Wong, RM | 1 |
| Dickmeiss, E; Heilmann, C; Jakobsen, B; Kornblit, B; Madsen, HO; Masmas, T; Olesen, G; Petersen, SL; Ryder, LP; Sengeløv, H; Svejgaard, A; Vindeløv, L | 1 |
| Beri, R; Chen, YH; Chunduri, S; Dobogai, LC; Hurter, E; Mahmud, N; Peace, D; Quigley, J; Rondelli, D; Saunthararajah, Y | 1 |
| Bari, A; Brugiatelli, M; Buda, G; Gobbi, PG; Lazzaro, A; Lombardo, M; Luminari, S; Marcheselli, L; Marcheselli, R; Morabito, F; Pozzi, S; Quarta, G; Sacchi, S; Stelitano, C | 1 |
| Friedberg, JW | 1 |
| Caballero, D; Calvo, MV; de la Cámara, R; de Oteiza, JP; Heras, I; Martino, R; Pérez-Simón, JA; Rebollo, N; San Miguel, JF; Sierra, J; Valcarcel, D | 1 |
| Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Jones, RB; Korbling, M; Pierre, B; Roberson, S; Russell, JA; Shpall, EJ; Thall, PF; Wang, X | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P | 1 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Anderlini, P; Estey, EH; Kantarjian, HM; Keating, MJ; Luna, M; O'Brien, S; Pierce, S | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Frewin, RJ; Provan, D; Smith, AG | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Bolam, S; Orchard, JA; Oscier, DG | 1 |
| Estey, EH | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Bouabdallah, R; Cohen-Valensi, R; Coso, D; Costello, R; Gastaut, JA; Nezri, M; Sainty, D | 1 |
| Ciolli, S; Ferrara, F; Leoni, F; Magrin, S; Mele, G; Mirto, S; Montillo, M; Morra, E; Pinto, A; Zagonel, V | 1 |
| Aul, C; Gattermann, N; Germing, U; Misgeld, E | 1 |
| Akiyama, H; Hiruma, K; Kaku, H; Karasawa, K; Kono, N; Maeda, Y; Mizuchi, D; Mori, S; Ohashi, K; Okamoto, R; Okoshi, Y; Okuyama, Y; Sakamaki, H; Sasaki, E; Sasaki, T | 1 |
| Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M | 1 |
| Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA | 1 |
| Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
5 review(s) available for fludarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Fludarabine: a review of the clear benefits and potential harms.
Topics: Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Vidarabine | 2013 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine | 1998 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
69 trial(s) available for fludarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2020 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).
Topics: Adult; Busulfan; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Prognosis; Quality of Life; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.
Topics: Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine | 2019 |
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Prospective Studies; Recurrence; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Reduced-toxicity myeloablative conditioning consisting of 8-Gy total body irradiation, cyclophosphamide and fludarabine for pediatric hematological malignancies.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Gamma Rays; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Quality of Life; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Risk; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2016 |
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mucositis; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; Child; Child, Preschool; Cyclophosphamide; Fanconi Anemia; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Siblings; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2017 |
Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neutropenia; Pneumonia; Prospective Studies; Rituximab; Survival Rate; Thrombocytopenia; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antibodies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Iodine Radioisotopes; Leukemia, Myeloid; Leukocyte Common Antigens; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis; Survival Rate; Tissue Distribution; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2009 |
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recurrence; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2010 |
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Medical Records; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2011 |
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Topics: Adult; Antineoplastic Agents; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
Topics: Adolescent; Adult; Anemia, Aplastic; Antibiotic Prophylaxis; Antilymphocyte Serum; Antiviral Agents; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Postoperative Complications; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Drug Therapy, Combination; Female; Gastroenteritis; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2013 |
Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Isogeneic; Vidarabine | 2002 |
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Vidarabine | 2002 |
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Follow-Up Studies; Graft Survival; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation, Homologous; Vidarabine | 2003 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate; Vidarabine | 2004 |
Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Topics: Busulfan; Humans; Leukemia; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Lymphoma; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Survival Analysis; Time Factors; Vidarabine | 2004 |
Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 7; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; DNA Damage; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Remission Induction; Rituximab; Time Factors; Vidarabine | 2005 |
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2005 |
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2005 |
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
Topics: Acute Disease; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Siblings; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2005 |
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Epidemiologic Methods; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2006 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survivors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Recurrence; Thiosemicarbazones; Treatment Outcome; Vidarabine | 2008 |
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gemtuzumab; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Transplantation, Homologous; Vidarabine | 2008 |
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Topics: Adult; Age Factors; Aged; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Disease-Free Survival; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Agents; Bayes Theorem; Busulfan; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2008 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Remission Induction; Sepsis; Treatment Failure; Vidarabine | 1996 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine | 2001 |
93 other study(ies) available for fludarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Propensity Score; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2021 |
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2021 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Topics: Adult; Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Propensity Score; Retrospective Studies; Vidarabine | 2022 |
Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Topics: Adolescent; Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Myelodysplastic Syndromes; Retrospective Studies; Siblings; Transplantation Conditioning; Young Adult | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients.
Topics: Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes | 2023 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.
Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Recurrence; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2019 |
Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2020 |
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Topics: Age Factors; Aged; Busulfan; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Radiation Dosage; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2020 |
Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Decitabine; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2020 |
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine | 2021 |
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes.
Topics: Aged; Busulfan; Graft vs Host Disease; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Vidarabine | 2021 |
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Databases, Factual; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Risk Factors; Rituximab; Vidarabine; Young Adult; Yttrium Radioisotopes | 2017 |
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; Hematopoietic Stem Cell Transplantation; HLA-C Antigens; Humans; Leukemia, Myeloid, Acute; Ligands; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, KIR; Recurrence; Retrospective Studies; Siblings; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2017 |
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Melphalan; Middle Aged; Myelodysplastic Syndromes; Rabbits; Risk Assessment; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2017 |
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Topics: Aged; Aged, 80 and over; Busulfan; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2017 |
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Topics: Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Ontario; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2018 |
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Topics: Aged; Busulfan; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2013 |
Fludarabine in Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Disease-Free Survival; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Comorbidity; Creatinine; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Rituximab; Vidarabine | 2013 |
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine | 2014 |
Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Vidarabine | 2015 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Lymphoproliferative Disorders; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2015 |
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2016 |
The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comorbidity; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Cells; Busulfan; Cyclophosphamide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine; Young Adult | 2016 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Recurrence; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Aged; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Transplantation Conditioning; Vidarabine; Young Adult | 2009 |
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Topics: Adolescent; Adult; Age Factors; Aged; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2010 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Thailand; Vidarabine; Young Adult | 2010 |
Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Assessment; Vidarabine | 2010 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2010 |
Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.
Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2011 |
Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Infections; Kaplan-Meier Estimate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cohort Studies; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prognosis; Retrospective Studies; Translocation, Genetic; Vidarabine | 2011 |
Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 20; Female; Flow Cytometry; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2011 |
Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukocyte Count; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Myelodysplastic Syndromes; Platelet Count; Statistics as Topic; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2011 |
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Rabbits; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Vidarabine | 2012 |
[Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].
Topics: Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Fatal Outcome; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Prednisone; Vidarabine; Vincristine | 2013 |
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Topics: Adult; Aged; Chemoprevention; Dose-Response Relationship, Drug; Drug Combinations; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Sirolimus; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation.
Topics: Adolescent; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukoencephalopathies; Male; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Vidarabine | 2013 |
Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy.
Topics: Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Time Factors; Vidarabine | 2012 |
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Agents; Dendritic Cells; Flow Cytometry; Fluorescent Antibody Technique; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Neoplasms; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Vidarabine | 2002 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine | 2003 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.
Topics: Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Culture Techniques; Cell Proliferation; Cell Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Immunosuppressive Agents; In Situ Hybridization, Fluorescence; Lewis X Antigen; Lipopolysaccharide Receptors; Lymphoma; Male; Microscopy, Fluorescence; Middle Aged; Myelodysplastic Syndromes; Nucleic Acid Synthesis Inhibitors; Stromal Cells; Transplantation Conditioning; Vidarabine | 2005 |
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Treatment Outcome; Vidarabine | 2005 |
Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Female; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Treatment Outcome; Vidarabine | 2006 |
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Drug Administration Schedule; Humans; Male; Monosomy; Myelodysplastic Syndromes; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Costs and Cost Analysis; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Living Donors; Melphalan; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine | 2006 |
[Inhibition effect of fludarabine on the growth of myelodysplastic syndrome cell line MUTZ-1 and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Survivin; Vidarabine | 2006 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Another case of myelodysplasia with monosomy 7 following fludarabine-based chemotherapy.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 7; Female; Humans; Lymphoma, Follicular; Middle Aged; Monosomy; Myelodysplastic Syndromes; Vidarabine | 2006 |
High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hematologic Neoplasms; Humans; Leukemia; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Humans; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Reoperation; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prognosis; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2007 |
Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Topics: Adult; Aged; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Topics: Adult; Aged; Denmark; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Hospitalization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Outpatient Clinics, Hospital; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Radiotherapy; Transplantation, Autologous; Vidarabine | 2008 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Chromosomes, Human, Pair 8; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia; Trisomy; Vidarabine | 1997 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
Association of myelodysplastic changes with purine analogues.
Topics: 2-Chloroadenosine; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxyadenosines; Female; Humans; Lymphoproliferative Disorders; Male; Myelodysplastic Syndromes; Pentostatin; Vidarabine | 1998 |
Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Fatal Outcome; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Vidarabine | 1999 |
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Vidarabine | 1999 |
Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Chromosome Aberrations; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Myelodysplastic Syndromes; Vidarabine | 2001 |
Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine | 2001 |
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell Count; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Karyotyping; Methotrexate; Middle Aged; Monosomy; Myelodysplastic Syndromes; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |